Systemic lupus erythematosus, sometimes known as SLE, is a type of autoimmune illness that can express itself in a dizzying array of different ways in patients. Atherosclerosis and the conditions that result from it are the leading causes of late mortality in people who have complications from SLE. Traditional risk factors, the presence of specific risk factors, the duration of the course, the use of glucocorticoids (GC), the presence of autoantibodies to double-stranded (native) DNA, and the presence of antiphospholipid antibodies all create conditions that accelerate the development of atherosclerosis in this group of patients. The research that is now available suggests that established risk factors for cardiovascular disease should be revised in order to take into consideration the beneficial effect of antimalarial medications as well as the unfavorable prognostic effect of prolonged use of GC.
Systemic lupus erythematosus, sometimes known as SLE, is a type of autoimmune illness that can express itself in a dizzying array of different ways in patients. Atherosclerosis and the conditions that result from it are the leading causes of late mortality in people who have complications from SLE. Traditional risk factors, the presence of specific risk factors, the duration of the course, the use of glucocorticoids (GC), the presence of autoantibodies to double-stranded (native) DNA, and the presence of antiphospholipid antibodies all create conditions that accelerate the development of atherosclerosis in this group of patients. The research that is now available suggests that established risk factors for cardiovascular disease should be revised in order to take into consideration the beneficial effect of antimalarial medications as well as the unfavorable prognostic effect of prolonged use of GC.
| № | Муаллифнинг исми | Лавозими | Ташкилот номи |
|---|---|---|---|
| 1 | Toshnazarova N.. | ! | Samarkand State Medical University |
| № | Ҳавола номи |
|---|---|
| 1 | 1.Асеева ЕА, Соловьев СК, Попкова ТВ и др. Ведение пациентов системной красной волчанкой в реальной клинической практике. //Научно-практическая ревматология. -2019;-No57 (2)-С.191-62.Насонов ЕЛ, редактор. Системная красная волчанка. //В кн.: Российские клинические рекомендации. Москва: ГЭОТАРМедиа; -2017. -С 113-41.3.Domer Т, Lipsky РЕ Beyond pan-B-cell-directed therapy -new avenues and insights into the pathogenesis of SLE.// Nat Rev Rheumatol. 2016;12:645-57. doi: 10.1038/nr-rheum.2016.1584.Guillot M, Rafat C. Buob D, et aL Eculizumab for catastrophic antiphospholipid syndrome -a case report and literature review.// Rheumatology (Oxford).-2018;57(11):2055-7. doi: 10.1093/rheumatology/key2285.Isenberg DA. Merrill JT. Why, why, why de-lupus (does so badly in clinical trials).// Expert Rev Clin Immunol. 2016;2:95-8. doi: 10.1586/1744666X.2016.11122706.Kaul A, Gordon C. Crow MK, et a). Systemic lupus erythematosus.// Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/ nrdp.2016.397.Lightstone L, Doria A, Wilson H. et al. Can we manage lupus nephritis without chronic corticosteroids administration? Independent association of glucocorticoids with damage accrual in SLE.//Autoimmun Rev. 2018;17(l):4-10. doi: 10.1016/j. autrev.2017.11.002 Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39.8.Little J, Parker B, Lunt M. et aL Glucocorticoid use and factors associated with variability in this use in the systemic lupus international collaborating clinics inception cohort.// Rheumatology. 2018;57:677-87. doi: 10.1093/rheumatology/ kex4449.Pisetsky DS. Bossuyt X, Meroni PL ANA as an entry criterion for the classification of SLE. // Autoimmun Rev. 2019 Oct 19:102400. doi: 10.1016/j.autrev.2019.10240010.Ruiz-Limon P. Barbarroja N. Perez-Sanchez C, et aL Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment. // Ann Rheum Dis. 2015;74(7):1450-8. doi: 10.1136/annrheum-dis-2013-20435111.Tsokos GC, Lo MS, Costa Reis P. Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. I/ Nat Rev Rheumatol. 2016; 12( 12):716-30. doi: 10.1038/ nrrheum.2016.18612.Chang HD, Tokoyoda K. Hoyer B, et aL Pathogenic memory plasma cells in autoimmunity. // Curr Opin Immunol. 2019;61:86-91. doi: 10.1016/j.coi.2019.09.00513.Little J, Parker B, Lunt M. et aL Glucocorticoid use and factors associated with variability in this use in the systemic lupus international collaborating clinics inception cohort.// Rheumatology. 2018;57:677-87. doi: 10.1093/rheumatology/ kex44414.Pisetsky DS. Bossuyt X, Meroni PL ANA as an entry criterion for the classification of SLE. // Autoimmun Rev. 2019 Oct 19:102400. doi: 10.1016/j.autrev.2019.10240015.Ruiz-Limon P. Barbarroja N. Perez-Sanchez C, et aL Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment. // Ann Rheum Dis. 2015;74(7):1450-8. doi: 10.1136/annrheum-dis-2013-20435116.Tsokos GC, Lo MS, Costa Reis P. Sullivan KE. New insightsinto the immunopathogenesis of systemic lupus erythematosus. I/ Nat Rev Rheumatol. 2016; 12( 12):716-30. doi: 10.1038/ nrrheum.2016.18617.Chang HD, Tokoyoda K. Hoyer B, et aL Pathogenic memory plasma cells in autoimmunity. // Curr Opin Immunol. 2019;61:86-91. doi: 10.1016/j.coi.2019.09.00518.Chang HD, Tokoyoda K. Hoyer B, et aL Pathogenic memory plasma cells in autoimmunity. // Curr Opin Immunol. 2019;61:86-91. doi: 10.1016/j.coi.2019.09.00519.Little J, Parker B, Lunt M. et aL Glucocorticoid use and factors associated with variability in this use in the systemic lupus international collaborating clinics inception cohort.// Rheumatology. 2018;57:677-87. doi: 10.1093/rheumatology/ kex44420.Pisetsky DS. Bossuyt X, Meroni PL ANA as an entry criterion for the classification of SLE. // Autoimmun Rev. 2019 Oct 19:102400. doi: 10.1016/j.autrev.2019.102400 |